

Ref. No: 2541  
Date: 30<sup>th</sup> April 20206  
Subject: Blood disorders

## REQUEST and RESPONSE

Information for Q1 2026 (January–March 2026).

**1) Please provide total volume (IU/mg) and, where available, total number of patients treated for the following products:**

- NovoSeven (eptacog alfa)
- Cevenfacta (eptacog beta)
- FEIBA (anti-inhibitor coagulant complex)
- Obizur (susoctocog alfa)
- Hemlibra (emicizumab) (*haemophilia A inhibitor patients only*)

The treatments listed in section 1 have not been given in the time frame provided.

**2) Where feasible from existing records, I would also welcome any available breakdown of these patient numbers and/or volumes by indication. For example:**

- haemophilia A with inhibitors
- haemophilia B with inhibitors
- Acquired haemophilia (AHA)
- Glanzmann thrombasthenia
- Factor VII deficiency
- other (please specify)

**Partial breakdowns (e.g. for only some indications) are welcome.**

**If this level of detail is not routinely captured, please provide the data in the closest available format, or without any indication breakdown.**

Conditions listed in section 2 are not managed at our hospitals and are instead cared for at the regional haemostasis centre in Liverpool Royal. Any new patient found to have one of these conditions would have their care transferred to Liverpool.

